Looking beyond short-term turmoil, Syngene is investing for the future - Pharmaceutical Technology

CRDMO Syngene has revamped its leadership and is building capacity as it eyes growth and emerging modalities. The CRDMO has revamped its leadership and is building capacity as it eyes growth and emerging modalities. The timing of the facility acquisition fits neatly with the ongoing US drive to onshore pharma manufacturing that began in 2025. Credit: WUT.ANUNAI via Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for news and procurement in…

Source: Pharmaceutical Technology